Bayer AG's book value per share for the quarter that ended in Mar. 2026 was CHF26.72.
During the past 12 months, Bayer AG's average Book Value Per Share Growth Rate was -11.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -12.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -2.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Bayer AG was 22.30% per year. The lowest was -13.90% per year. And the median was 1.50% per year.
Bayer AG's current price is CHF43.29. Its book value per share for the quarter that ended in Mar. 2026 was CHF26.72. Hence, today's PB Ratio of Bayer AG is 1.62.
During the past 13 years, the highest P/B Ratio of Bayer AG was 3.57. The lowest was 0.58. And the median was 1.45.
Warning Sign:
Bayer AG stock PB Ratio (=1.6) is close to 3-year high of 1.74.
Bayer AG (XSWX:BAYN) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Bayer AG Book Value per Share Related Terms
Bayer AG Book Value per Share Historical Data
* Premium members only.
The historical data trend for Bayer AG's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BAYN vs LLY, JNJ, ABBV: Book Value per Share Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bayer AG's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of CHF26.72 mean?
Bayer AG (XSWX:BAYN) has a Book Value per Share of CHF26.72 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bayer AG and its competitors.
Is Bayer AG's Book Value per Share too high?
Bayer AG's current Book Value per Share is CHF26.72. Overall, Bayer AG has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Book Value per Share compare to LLY and JNJ?
Bayer AG's Book Value per Share of CHF26.72 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bayer AG and its competitors. Bayer AG's current Book Value per Share is CHF26.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.61, compared to a current price of CHF43.29 — trading 75.9% above its estimated fair value. The current Book Value per Share is CHF26.72. Bayer AG's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Book Value per Share is CHF26.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF43.29 is trading 75.9% above its estimated GF Value™ of CHF24.61.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
Book Value per Share: CHF26.72
GF Value™: CHF24.61 vs. price of CHF43.29 (75.9% above fair value)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
54GF Score
Get the complete analysis for XSWX:BAYN
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
